Up-to-date data are needed on the types of treatments used by psychiatrists and the reasons for use of particular treatments. Using 1997 American Psychiatric Association (APA) Practice Research Network (PRN) Study data on patients with schizophrenia and other psychotic disorders, we identified the characteristics of antipsychotic medications (APMs) currently being prescribed and factors associated with the use of particular regimens. In this study population, use of the newer APMs, including risperidone, olanzapine, and clozapine, has increased rapidly and now accounts for over one-half of all APM use. Other intriguing findings include the fact that one-sixth of patients with schizophrenia and other psychotic disorders are concurrently treated with two or more APMs. Factors associated with being prescribed one of the newer APMs risperidone or olanzapine include being elderly, having more education, being white, having psychiatric comorbidity, and making fewer recent visits to a psychiatrist. The APA PRN Study data are an important new resource for mental health services researchers.
Schizophrenia and other psychotic disorders constitute an enormous public health problem that places significant burdens on patients and their families (McGlashan 1988) . The care of such patients falls largely into the hands of psychiatrists who are faced with an increasingly complex choice of pharmacological treatments (Frances et al. 1996; APA 1997; Lehman and Steinwachs 1998) . This increasing complexity is due in part to the availability of several newer APMs, including clozapine, risperidone, olanzapine, and quetiapine.
An important task for mental health services researchers has been to understand what kinds of treatments are currently being offered to this often vulnerable patient population. Another equally important task has been to identify the influences on and reasons for a psychiatrist's choice of medication regimen, including scientific, clinical, administrative, economic, political, and other factors that may affect the provision of care. However, there is a dearth of knowledge concerning the characteristics of patients, prescribers, treatment settings, and health care systems that predict the use of particular pharmacological regimens for die treatment of psychotic disorders. Lastly, it has been imperative to develop data sources for studies of the clinical outcomes obtained with treatments among "real-world" patient populations as well as the outcomes associated with the use of "unconventional" medication regimens that are used in clinical practice but have not been studied in clinical trials (Lehman 1996) .
Empirical data on the patterns, predictors, and outcomes of pharmacological treatments provided to patients with schizophrenia and other psychotic disorders are crucial for bodi understanding and monitoring the care given to this vulnerable population and guiding important clinical and policy decision making and quality improvement efforts (Lehman et al. 1995) .
Methods
All data were obtained from the 1997 APA PRN Study of Psychiatric Patients and Treatments. The rationale for the PRN Study, descriptions of the methods employed, and studies employing PRN data have been published previously (Zarin et al. 1997; Zarin et al. 1998; Pincus et al. 1999) . Psychiatrists participating in the PRN Study consisted of 224 randomly recruited individuals and 307 selfidentified volunteers. Self-selected volunteers were nation- ally recruited for participation in the PRN Study because experience in other established practice-based networks stressed the importance of their role in facilitating the successful conduct of studies (Zarin et al. 1997) . Analytic comparisons of 78 sociodemographic and practice variables (e.g., age, gender, board certification status, and practice variables such as setting and health plan type) have shown that PRN members are generally representative of the APA membership as a whole (Pincus et al. 1999) , which includes a majority of psychiatrists in the United States. Statistically significant differences between PRN members and APA membership were observed on only four of these variables and were taken into account when calculating all sampling weights (Pincus et al. 1999 ).
Information for this study was provided by the 78 percent (417 of 531) of PRN psychiatrists who provided patient-level data on 1,245 patients. All psychiatrists were asked to complete a detailed diagnostic and treatment form for three patients who had been randomly preselected on a patient log. Information collected included detailed demographic, diagnostic, clinical, treatment, health care system, and treatment setting information.
All analyses of psychopharmacologic treatments in this study were conducted among the 154 patients reported to have a DSM-IV diagnosis of schizophrenia or other psychotic disorder (including schizophrenia, schizophreniform, schizoaffective, shared psychotic, and psychotic disorders not otherwise specified, but not delusional disorder or psychotic disorders resulting from general medical conditions or substances). Analyses of the predictors of the use of a newer APM were conducted among the 146 patients with schizophrenia and other psychotic disorders who were being given an APM at the time of the survey.
All analyses were performed using SAS and SUDAAN software to adjust for the complex sampling design. Basic weighted descriptive statistics were calculated, and the statistical significance of differences between groups was evaluated with chi-square tests (for categorical variables) and / statistics (for continuous measures).
In univariate screens, we identified all patient, prescriber, and health care system variables that were at least weakly associated (at the p s 0.2 level) with the use of the newer APMs risperidone or olanzapine. (Note that "newer APM use" does not include quetiapine or clozapine use because quetiapine was not yet available for use when this study was conducted, and the reasons for clozapine use, such as treatment resistance, were felt to be significantly different from those for other newer APMs.) All covariates associated with use of newer APMs at the p s 0.20 significance level were then included in a multiple logistic regression model of the probability of newer APM use among users of any APM; all included covariates were then subjected to a stepwise, backward selection procedure. Independent effects of statistically significant (at the p s 0.05 level) predictors were identified from this model. In all analyses, standard errors were adjusted for clustering of patients within psychiatrists' practices using SUDAAN software.
Results
The characteristics of patients with schizophrenia and other psychotic disorders in the PRN study appear in table 1. Most patients were adults and white; over 50 percent were male and never married. Nearly 50 percent had at least some high school education, and almost 30 percent had more years of education beyond high school. Over 37 percent had at least one comorbid Axis I psychiatric condition. The most common comorbid psychiatric conditions in the patient sample were substance-related (26%), personality (12%), and anxiety (6%) disorders. Nearly 65 percent of patients had at least one visit with the psychiatrist in the past month, and over 37 percent had two or more visits. The proportions of patients with schizophrenia and other psychotic disorders who were prescribed particular APM regimens appears in figure 1 . Nearly all patients with a psychotic disorder (95%) were being treated with at least one APM at the time of the survey, 15 percent were receiving two APMs concurrently, and 2 percent were receiving three or more APMs concurrently. In terms of use of specific antipsychotic agents, 24 percent of patients with a psychotic disorder were receiving risperidone, and another 23 percent were receiving olanzapine; 7 percent were receiving clozapine.
Covariates that were found in univariate screens to be associated with use of newer APMs (at the p s 0.20 significance level) appear in table 2. Results of a multiple logistic regression model of the probability of newer APM use among users of any APM that included these covariates appear in table 3. Elderly patients receiving an APM were 11 times more likely to be prescribed a newer APM than younger adults receiving an APM. There was a tendency for nonwhite patients to be less likely than whites to receive a newer APM. Patients not completing high school education were also only one-tenth as likely to receive a newer APM compared to patients receiving some high school education. There was a fivefold increase in the use of newer APMs among patients with comorbid Axis I conditions relative to patients without such comorbidities. Patients making two or more visits to the psychiatrist in the past month were only one-fifth as likely to be taking a newer APM relative to patients making fewer visits.
Discussion
There have been significant recent changes in the use of APMs to treat schizophrenia and other psychotic disorders. In particular, there has been an extremely rapid rise in the use of newer APMs, such as risperidone, olanzapine, and clozapine; use of these newer medications in 1997 appeared to account for over half of all APM use. The reasons for this rapid rise, including the possibility that psychiatrists are finding that these antipsychotic agents possess differential efficacy or tolerability in "realworld" settings, require further investigation. Other characteristics of current antipsychotic treatments for schizophrenia and other psychotic disorders are both notable and intriguing. One in six patients with schizophrenia and other psychotic disorders was being treated concurrently with two or more APMs. Again, the reasons for this prevalence of concurrent use of multiple antipsychotic agents are unclear, possible reasons include that prescribing psychiatrists observe greater effectiveness for such APM combinations than single agents or experience difficulty in completing titrations from one APM to another. Information on prior treatment history, clinical decision making, and patient outcomes with such unconventional regimens are unavailable from clinical trial data but may be possible in the future using followup data from the PRN Study.
In this study we examined the potential of using PRN Study data for identifying factors associated with psychiatrists' prescription of particular treatments. We were able to identify several factors that are associated with the use of the newer APMs olanzapine and risperidone. The greater likelihood of older subjects to be given a newer APM may be due to the fact that the elderly are more vulnerable to side effects (e.g., extrapyramidal and anticholinergic) that are more prevalent with older agents.
The increased likelihood of patients with comorbid Axis I conditions to receive newer APMs may also be traced to psychiatrists' perceptions that newer APMs are safer among patients with additional nonpsychotic symptomatology or other non-APM medications. Patients making multiple visits to their psychiatrist in the prior month may represent patients who have decompensated or have a greater level of acuity. Several hypotheses could explain why such patients are less likely to be prescribed newer APMs, and these hypotheses should be investigated in future studies: newer APMs may be perceived to be less effective for such acute patients, patients prescribed newer APMs may be less likely to decompensate, and patients on older APMs who are highly symptomatic may be reluctant to try switching to newer agents.
Several reasons could also explain why nonwhite patients and patients of lower education levels are less likely to receive newer APMs. The higher costs of newer APMs could present a significant financial burden and diminish their use among patients who may have limited financial resources and lack prescription benefits. However, it is worth noting that additional adjustment of the model for source of payment (e.g., Medicaid, Medicare, private/commercial insurance), which may act as a proxy variable for socioeconomic status and access to prescription benefits, did not significantly alter the findings regarding the lower likelihood of nonwhite patients and patients of lower education levels to be given newer APMs. Further study is necessary to clarify whether these findings concerning race and education are due to potential prescribing biases of providers, confounding from factors such as severity of illness or vulnerability to side effects, or other methodological considerations. Other patient (demographic and clinical), psychiatrist, treatment setting, and health care system variables did not significantly predict the use of newer APMs. The degree to which the lack of power underlies any absence of association should also be explored in future studies.
The limitations of this study deserve mention and consideration. These results are based on relatively small numbers of patients with schizophrenia and other psychotic disorders and using particular APM treatments. In the future, additional power to study some questions may be obtained by combining PRN Study data from multiple years. The cross-sectional nature of this PRN survey makes it difficult to determine if factors associated with APM treatments are etiologically related to or result from particular pharmacological regimens. Future prospective and longitudinal PRN Study data may help clarify the nature of these relationships.
Although the PRN Study contains many randomly selected psychiatrists, over half of psychiatrists were selfselected volunteers, raising the possibility that results generated with PRN Study data may not be nationally representative of all psychiatrists (Pincus et al. 1999 ). In addition to considering whether PRN Study psychiatrists are nationally representative, it is also important to consider whether PRN Study patients with schizophrenia and other psychotic disorders are representative of all patients with these disorders in the United States. The substantial number of patients with schizophrenia and other psychotic disorders who receive no treatment (Attkisson et al. 1992 ; Department of Health and Human Services 1992) or receive treatment from practicing psychiatrists not in the APA may differ in important ways from patients described in the PRN Study. The extent and ways in which PRN Study psychiatrists and their patients are not nationally representative will require additional study in the future. Lastly, it is possible that the associations observed between patient features and use of newer APMs arose by chance because of multiple comparisons.
Despite such potential limitations, PRN Study data appear to be a valuable source of timely information on the current characteristics and recent changes in treatments, as well as important patient, prescriber, and health care system factors related to the use of particular regimens. Such information, together with data on the outcomes of treatments, is sorely needed to guide clinical and policy decision making and improve the well-being of psychiatric patients. psychiatric practice. Journal of the American Academy of Child and Adolescent Psychiatry, 37:1262 -1270 ,1998 
